The innovative artificial joint company b-ONE successfully closed a B-round financing of several hundred of million RMB, marking it the the largest RMB financing in the domestic orthopedic joint sector in recent years. The funding was led by Huatai Zijin Investment, with participation from Agricultural Bank Financial Assets Investment and Hubei Provincial High Technology. Existing shareholder Eight Roads continued to invest. This demonstrates institutional investors' confidence in b-ONE's future development amidst the environment of centralized drug procurement.

CEC Capital Group served as the exclusive financial advisor in this transaction for b-ONE.

b-ONE is one of a few orthopedic joint companies with a global footprint. Since its inception in 2015, the company established a research and development center in the United States, dedicating itself to innovative designs of joint implants and tools, research and development of new orthopedic materials, and the establishment of the next-generation orthopedic digitalization. With strong research and development capabilities, b-ONE has achieved remarkable success in its six years of operation. Not only is b-ONE the only Chinese joint company to receive approvals for hip and knee joint implants from both the FDA and NMPA, their products have also obtained certifications in Southeast Asian regions, including Singapore, New Zealand, Vietnam, Thailand, and Hong Kong. On April 2, 2021, b-ONE's groundbreaking new product, Kosmo Hip Joint, obtained FDA approval for market launch. This product is the fourth artificial joint system approved by the FDA within four years after b-ONE entered the US market, marking a significant milestone in the company's product development and commercialization. b-ONE is one of the few Chinese joint enterprises with "overseas research and development, Chinese manufacturing, and global sales" capabilities.